Cell Cycle

SkinCeuticals Announces Miami Stop on National Treatment Tour

Retrieved on: 
Thursday, February 22, 2024
SVG, Education, Cell Cycle, Lincoln, Euclid Avenue, Lincoln Road

NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Following the success of its inaugural stop in New York in September 2023, SkinCeuticals, the #1 Medical Aesthetic Skincare Brand1 worldwide with 20 years of Integrated Skincare expertise, announces the second stop on its national Treatment Tour. Set to take place during the South Beach Wine & Food Festival, the SkinCeuticals Treatment Tour aims to redefine skincare education, offering an opportunity for consumers to experience 1:1 access to top medical professionals while celebrating the launch of SkinCeuticals newest product launch, Cell Cycle Catalyst.

Key Points: 
  • NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Following the success of its inaugural stop in New York in September 2023, SkinCeuticals, the #1 Medical Aesthetic Skincare Brand1 worldwide with 20 years of Integrated Skincare expertise, announces the second stop on its national Treatment Tour.
  • From Saturday, February 24th to Sunday, February 25th, the SkinCeuticals Treatment Truck will be in Miami at the Lincoln Center parked at Euclid Avenue and Lincoln Road.
  • "Activating in Miami as the second location for the SkinCeuticals Treatment Truck was a natural choice," said Angela Hildebrand, General Manager of SkinCeuticals US.
  • Treat yourself by visiting the SkinCeuticals Treatment Truck at Lincoln Center (Euclid Avenue and Lincoln Road) from February 24th to February 25th:
    To learn more about the national SkinCeuticals Treatment Tour, partake in a virtual Treatment Truck preview and book a SkinCeuticals complimentary Treatment, please visit https://www.skinceuticals.com/skincare-services/treatment-tour.html .

SkinCeuticals Announces the Launch of Cell Cycle Catalyst

Retrieved on: 
Thursday, February 15, 2024
Cosmeceutical, Ageing, Cell Cycle, Skin, Cell, Head, Fine chemical

NEW YORK, Feb. 15, 2024 /PRNewswire/ -- SkinCeuticals, the #1 Medical Skincare Brand, announces the launch of Cell Cycle Catalyst. This new, innovative lightweight serum was developed to improve the efficacy of anti-aging treatments, both at home and in-office.

Key Points: 
  • NEW YORK, Feb. 15, 2024 /PRNewswire/ -- SkinCeuticals, the #1 Medical Skincare Brand, announces the launch of Cell Cycle Catalyst.
  • SkinCeuticals Cell Cycle Catalyst addresses key signs of aging head-on, providing a comprehensive solution to accelerate cellular turnover, boost cellular energy and vitality, stimulate barrier renewal, and eliminate dead surface cells.
  • "SkinCeuticals Cell Cycle Catalyst represents the next evolution in skincare innovation," says Angela Hildebrand, General Manager of SkinCeuticals U.S. "Cell Cycle Catalyst exemplifies our positioning as a pioneer in cosmeceuticals and our dedication to delivering transformative results to our customers both at-home and in tandem with their clinical procedures in-office."
  • "Cell Cycle Catalyst triggers 'cell cycling,' to eliminate dead skin cells and activate new skin cells, resulting in amplified at-home skincare benefits and increased receptivity of in-office clinical procedures."

Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

Retrieved on: 
Tuesday, December 12, 2023
Diarrhea, Breast, Ibrutinib, Cell Cycle, Result, Neutropenia, Letrozole, DNA, Metabolism, G1, Society, Therapy, Cancer, ASH, DNA repair, Vivo, Ovary, Poster, Patient, Safety, MCL, Pharmaceutical industry

NEWTOWN, Pa., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preclinical data, highlighting narazaciclib’s preclinical activity in Bruton’s kinase inhibitor (BTKi)-resistant mantle cell lymphoma (MCL), in a poster presented on December 11, 2023 at the 65th Annual Meeting of the American Society for Hematology (ASH 2023) in San Diego.

Key Points: 
  • “We are pleased to have shared data at ASH 2023 from preclinical studies with narazaciclib in MCL models.
  • The data presented at SABCS highlight narazaciclib’s multi-kinase activity, its ability to target resistance pathways missed by other CDK4/6 inhibitors, and its differentiated anti-tumor and immunomodulatory activity.
  • Cell Cycle Blockade: The combination of narazaciclib plus ibrutinib induces a superior G1 cell cycle blockade in both ibrutinib-sensitive and ibrutinib-resistant MCL cells.
  • A copy of the poster is available on the “ Scientific Presentations ” section of the Onconova website.

Vizgen’s Presentations at AACR 2023 Annual Meeting Showcase Cellular and Subcellular Tumor Characterization Using New Pre-Designed PanCancer Pathways Panel

Retrieved on: 
Friday, April 14, 2023
Oncology, Medical Devices, Health, Stem Cells, Genetics, Biotechnology, Tissue, MYC, AACR, Hepatocellular carcinoma, Cancer, Hallmark, Lung cancer, Breast, Research, Prostate, MIT, Doctor of Philosophy, Harvard University, Lung, Colon, PI3K, Panel, MD, The Cancer Genome Atlas, Cell Cycle, Gene, Medical imaging

Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today unveiled the MERSCOPE® PanCancer Pathways Panel.

Key Points: 
  • Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today unveiled the MERSCOPE® PanCancer Pathways Panel.
  • The company will be presenting data generated using the PanCancer Pathways Panel at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023 in Orlando, Florida.
  • The PanCancer Pathways Panel features a list of genes targeting canonical signaling pathways of cancer and is constructed using recognized oncology databases including OncoKB®, MutSig, the Cancer Genome Atlas and Hallmarks of Cancer to ensure inclusion of critical cancer genes.
  • The Panel provides a key tool for researchers to study tumor behavior at cellular and subcellular levels across multiple different types of cancers.

2022 Asia-Pacific Hematology and Flow Cytometry Analyzer and Reagent Markets

Retrieved on: 
Tuesday, November 1, 2022
Data pack, DNA, CD34, Assessment, Kinetics, Cell Cycle, Flow cytometry, Present value of growth opportunities, PDF, Hematology, 3D cell culture, Laser, Microsoft Excel, Platelet, BD (company), Chromosome, Adult T-cell leukemia/lymphoma, POC, Lymphocyte, Fine chemical, Retail, Vaccine, Microscope, Hospital

The survey is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities emerging in the hematology and flow cytometry markets during the next five years.

Key Points: 
  • The survey is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities emerging in the hematology and flow cytometry markets during the next five years.
  • Continued advances in molecular diagnostics, monoclonal antibodies, lasers and IT, as well as growing understanding of immunologic forces regulating systemic diseases, will have a profound impact on the hematology and flow cytometry markets.
  • The introduction of smaller and easy-to-operate laser systems will further expand applications of flow cytometry to routine clinical laboratories.
  • - Sales and market share estimates of leading hematology and flow cytometry product suppliers in major countries.

The Refined Medicine Institute of Nevada Announces Rapamycin Anti-Aging Therapy

Retrieved on: 
Wednesday, February 9, 2022
Ageing, Growth, Mouse, Cell Cycle, Inflammation, MTOR, Primate, FDA, Mikhail Blagosklonny, American Academy, Human, Science, Life, Dog, Health, Leigh syndrome, Autophagy, Regenerative medicine, Anti-aging movement, Disease, Cancer, Mitochondrial disease, Pharmaceutical industry, Dentistry, Sirolimus

LAS VEGAS, Feb. 9, 2022 /PRNewswire/ --The Refined Medicine Institute of Nevada, a medical center and leading edge practice of regenerative medicine, is excited to announce the availability of Rapamycin anti-aging therapy to fight the effects of aging and inflammation.

Key Points: 
  • LAS VEGAS, Feb. 9, 2022 /PRNewswire/ --The Refined Medicine Institute of Nevada, a medical center and leading edge practice of regenerative medicine, is excited to announce the availability of Rapamycin anti-aging therapy to fight the effects of aging and inflammation.
  • Originally Rapamycin (aka Sirolimus) was utilized during kidney transplant procedures to prevent organs from being rejected.
  • In a study, Rapamycin, an mTOR inhibitor, extended the life span of a particular strain of mice nearly three-fold2.
  • Rapamycin has also been shown to be effective at slowing down aging in dogs, primates, and humans.

CDK Global to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on August 17, 2021

Retrieved on: 
Thursday, July 15, 2021
CDK Global, Cell Cycle, Companies, CDK, NASDAQ, Cyclin-dependent kinase, Finance

HOFFMAN ESTATES, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- CDK Global, Inc. (Nasdaq: CDK), a leading retail automotive technology company, is scheduled to release its financial results for the fiscal fourth quarter and year ended June 30, 2021 after the closing of the Nasdaq market on Tuesday, August 17, 2021.

Key Points: 
  • HOFFMAN ESTATES, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- CDK Global, Inc. (Nasdaq: CDK), a leading retail automotive technology company, is scheduled to release its financial results for the fiscal fourth quarter and year ended June 30, 2021 after the closing of the Nasdaq market on Tuesday, August 17, 2021.
  • CDK will also be hosting a conference call at 4:00 p.m. CT on August 17, 2021 to discuss the results for the period.
  • A supplemental slide presentation will be available approximately 30 minutes before the webcast on the CDK Investor Relations home page.
  • CDK Global (Nasdaq: CDK) is a leading provider of integrated data and technology solutions to the automotive, heavy truck, recreation, and heavy equipment industries.

Role of Subnuclear NSrp70 in Immunity: Research at the Gwangju Institute of Science and Technology

Retrieved on: 
Thursday, July 15, 2021
Branches of biology, Medical specialties, Biology, Immune system, Immunology, T cell, Cell Cycle, Lymphocytes, Clusters of differentiation, PRDM1, Protein THEMIS

In 2011, scientists from the Gwangju Institute of Science and Technology (GIST) in Korea discovered a protein called NSrp70, which is abundant in motile T cells.

Key Points: 
  • In 2011, scientists from the Gwangju Institute of Science and Technology (GIST) in Korea discovered a protein called NSrp70, which is abundant in motile T cells.
  • With this knowledge, the scientists have been speculating about the possible role NSrp70 plays in the alternative splicing involved in T cell maturation and development.
  • They report that NSrp70 is expressed very early in the cell cycle and plays an important role in T cell development.
  • Prof. Jun sums up the findings emphatically, "Our study revealed that NSrp70 is an important regulator of T cell proliferation.

TruDiagnostic licenses Mitotic Clock developed by Van Andel Institute and Cedars-Sinai Medical Center

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Cell Cycle, In science, Mitosis, Van Andel, Cellular processes

GRAND RAPIDS, Mich. & LEXINGTON, Ky., July 13, 2021 /PRNewswire/ -- Today, TruDiagnostic licensed a Mitotic Clock developed by epigenetic pioneers at Van Andel Institute and Cedars-Sinai Medical Center, and will be working with Van Andel Institute to continue to develop and refine this new clock.

Key Points: 
  • GRAND RAPIDS, Mich. & LEXINGTON, Ky., July 13, 2021 /PRNewswire/ -- Today, TruDiagnostic licensed a Mitotic Clock developed by epigenetic pioneers at Van Andel Institute and Cedars-Sinai Medical Center, and will be working with Van Andel Institute to continue to develop and refine this new clock.
  • A fully developed Mitotic Clock could become extremely useful in both clinical research and personalized medicine...
    Mitosis is the process by which nearly all human and animal cells divide and replicate.
  • A Mitotic Clock looks at how many times a cell has undergone replication.
  • A fully developed Mitotic Clock could become extremely useful in both clinical research and personalized medicine with its ability to detect:
    Cell Senescence.

Carketa, Inc. Joins CDK Global Partner Program

Retrieved on: 
Monday, July 12, 2021
Computing, Cell Cycle, CDK, Cyclin-dependent kinase, Software, Companies

"We're very pleased to introduce Carketa as the newest member of the CDK Global Partner Program," said Howard Gardner, vice president and general manager, CDK Data Services. "

Key Points: 
  • "We're very pleased to introduce Carketa as the newest member of the CDK Global Partner Program," said Howard Gardner, vice president and general manager, CDK Data Services. "
  • The CDK Global Partner Program provides its partners with access to a diverse CDK ecosystem through the ability to integrate with a range of CDK applications, as well as with CDK dealer websites.
  • The CDK Partner Program now numbers more than 430 partner companies and 600 unique applications auto dealers can use to run their businesses.
  • As part of the CDK ecosystem, the CDK Partner Program provides data and workflow integration to a wide range of third parties, OEMs and dealers.